No benefit to letrozole treatment breaks, trial shows

5 June 2017

international_breast_cancer_study_group_large-1-

Taking three-month breaks during long-term treatment with letrozole did not reduce the risk of recurrence of breast cancer compared with taking the aromatase inhibitor continuously for five years among postmenopausal women with hormone-sensitive early breast cancer who had already completed four to six years of therapy.

That is the finding from a Phase III trial of letrozole, which is marketed by Swiss pharma giant Novartis (NOVN: VX) under the name Femara, but is available as a generic.

Results from the Study of Letrozole Extension (SOLE) trial were presented by the International Breast Cancer Study Group at ASCO 2017 on Monday.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK